Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Voyager Therapeutics (VYGR) Short-term Investments: 2015-2025

Historic Short-term Investments for Voyager Therapeutics (VYGR) over the last 10 years, with Sep 2025 value amounting to $163.8 million.

  • Voyager Therapeutics' Short-term Investments fell 29.65% to $163.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $163.8 million, marking a year-over-year decrease of 29.65%. This contributed to the annual value of $195.3 million for FY2024, which is 20.51% up from last year.
  • Voyager Therapeutics' Short-term Investments amounted to $163.8 million in Q3 2025, which was down 4.57% from $171.7 million recorded in Q2 2025.
  • In the past 5 years, Voyager Therapeutics' Short-term Investments ranged from a high of $294.9 million in Q2 2024 and a low of $5.0 million during Q1 2023.
  • Its 3-year average for Short-term Investments is $169.0 million, with a median of $171.7 million in 2025.
  • Per our database at Business Quant, Voyager Therapeutics' Short-term Investments tumbled by 85.72% in 2023 and then spiked by 5,036.99% in 2024.
  • Over the past 5 years, Voyager Therapeutics' Short-term Investments (Quarterly) stood at $15.1 million in 2021, then skyrocketed by 31.66% to $19.9 million in 2022, then skyrocketed by 714.89% to $162.1 million in 2023, then grew by 20.51% to $195.3 million in 2024, then dropped by 29.65% to $163.8 million in 2025.
  • Its Short-term Investments was $163.8 million in Q3 2025, compared to $171.7 million in Q2 2025 and $161.3 million in Q1 2025.